All you need to get started with ETF selection and analysis. Create your account now →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›State Street Investment Management›XPH

XPH

State Street SPDR S&P Pharmaceuticals ETF

Passive ETF Equity

The XPH Exchange Traded Fund (ETF) is provided by State Street Investment Management. It is built to track an index: S&P Pharmaceuticals Select Industry Index. The XPH ETF provides physical exposure, so by buying it you actually own parts of all the 62 underlying holdings. This share class generates a stream of income by distributing dividends.

$62.07

-$0.03 (-0.05%) yesterday

1:30 PM 10/14/26 Closed

1D price range

$61.87$63.10

52W price range

$46.90$74.35

YTD Perf.

+11.04%

YTD Flows

Annualized volatility

Fund AuM

€399M

Share class AuM

€399M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US78464A7220

TER

0.35%

Inception date

6/19/2006

Issuer

State Street Investment Management

Benchmark

S&P Pharmaceuticals Select Industry Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
CURE Global X S&P Biotech ETF	-2.82%
PSCH Invesco S&P SmallCap Health Care ETF	+0.81%
XHE State Street SPDR S&P Health Care Equipment ETF	+0.98%
BBC Virtus LifeSci Biotech Clinical Trials ETF	-5.85%
ARKG ARK Genomic Revolution ETF	-6.40%
AAKG ARK Genomic Revolution UCITS ETF	-6.21%
PTH Invesco DWA Healthcare Momentum ETF	-2.27%
BBP Virtus LifeSci Biotech Products ETF	-0.48%
SBIO ALPS Medical Breakthroughs ETF	-5.27%
IBRN iShares Neuroscience and Healthcare ETF	-5.67%
WDNA WisdomTree BioRevolution UCITS ETF	-1.48%
PJP Invesco Dynamic Pharmaceuticals ETF	+0.15%
PBE Invesco Dynamic Biotechnology & Genome ETF	+0.14%
HELX Franklin Genomic Advancements ETF	-3.01%
FMED Fidelity Disruptive Medicine ETF	-2.51%

API

PerformanceDec 31, 2025 - Oct 13, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 08/31/26

Healthcare

93.27%

Unavailable

6.73%

Latest XPH news

No content available for this fund

FAQ about XPH

XPH is a Passive ETF. This ETF provides exposure to Equally Weighted US Pharmaceuticals Equities.

XPH tracks the S&P Pharmaceuticals Select Industry Total Return Index - USD, through a full replication replication method.

XPH carries a total expense ratio (TER) of 0.35%, indicating the annual cost for holding the fund.

XPH was introduced to the market on June 19, 2006. It trades on United States

State Street SPDR S&P Pharmaceuticals ETF, XPH, is provided by State Street Investment Management. Learn more about State Street Investment Management here.

XPH oversees €399M in assets as of October 13, 2026.

XPH follows a distributing dividend policy, meaning it pays out income to investors. As of October 13, 2026, its 12-month trailing yield was 0.44%.

As of August 31, 2026, XPH has significant geographic allocations in USA and Ireland.

As of August 31, 2026, XPH focuses largely on Healthcare.

As of August 31, 2026, XPH holds 62 positions in its portfolio, with 34.13% of assets concentrated in its top 15 holdings.

As of August 31, 2026, XPH top three holdings include Amylyx Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc. and MBX Biosciences, Inc..

The base currency of XPH is USD.

Top 10 holdings

Data as of 08/31/26

Amylyx Pharmaceuticals, Inc.

3.65%

Crinetics Pharmaceuticals, Inc.

3.60%

MBX Biosciences, Inc.

2.89%

Omeros Corp.

2.68%

Enliven Therapeutics, Inc.

2.28%

Nuvation Bio, Inc.

2.12%

Corcept Therapeutics, Inc.

2.11%

Eton Pharmaceuticals, Inc.

2.08%

Perrigo Co. Plc

1.91%

Edgewise Therapeutics, Inc.

1.85%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

State Street SPDR S&P Pharmaceuticals ETF

FAQ about XPH

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US